Merck is in talks to acquire Revolution Medicines in a deal that could value the cancer-drug biotech at around $30 billion
WSJ·2026-01-10 03:58Revolution is developing drugs that target a molecular driver of cancers. ...
WSJ·2026-01-10 03:58 WSJ·2026-01-10 03:58